Adapt Pharma announced this week that Mike Kelly has joined the pharmaceutical firm as President of U.S. Operations.
With nearly 30 years of experience in the pharmaceutical industry, Kelly has served as CEO at Covis Pharmaceuticals Inc. and on the management team of Azur Pharma at its founding.
"I am delighted to welcome Mike to Adapt Pharma," Chairman and CEO Seamus Mulligan said. "Mike has established a highly successful track record in leadership roles in specialty pharmaceuticals. His experience will be of great value as Adapt Pharma expands its commercial presence, starting with the launch of NARCAN (naloxone HCl) Nasal Spray."
Among the pharmaceuticals under Kelly's management is NARCAN Nasal Spray. This new product allows emergency personnel and untrained bystanders to reverse opioid overdoses. Adapt Pharma has partnered with the Clinton Foundations Health Matters Initiative to offer this FDA-approved medication to U.S. high schools at no cost.
"I am excited to take on this role and look forward to working with our talented senior leadership to grow Adapt Pharma in the U.S.," Kelly said. "Most immediately, I am proud to support a product like NARCAN Nasal Spray and expand the opportunity to help Americans impacted by opioid overdose in our country."